Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Oxybutynin transdermal gel - Antares

Drug Profile

Oxybutynin transdermal gel - Antares

Alternative Names: Anturol; AP-1034; Gelnique 3% Gel; Oxybutynin ATD™ gel

Latest Information Update: 15 Jul 2015

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Antares Pharma
  • Developer Allergan; Antares Pharma
  • Class Alkynes; Antispasmodics; Carbocyclic acids; Cyclohexanes; Diethylamines; Esters; Mandelic acids; Small molecules
  • Mechanism of Action Cholinergic receptor antagonists; Muscarinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Overactive bladder

Most Recent Events

  • 25 Jan 2013 Watson Pharmaceuticals is now called Actavis, Inc.
  • 26 Apr 2012 Launched for Overactive bladder in USA (Transdermal)
  • 17 Jan 2012 Oxybutynin transdermal gel licensed to Daewoong Pharmaceuticals in South Korea
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top